Physician profile
Andrea Gallagher
NPI 1629669213
$3,472.70
in general payments reported to CMS, 2019-2025
19 companies · $1,642 in 2025
The $1,642 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $406 · 2023: $805 · 2024: $620 · 2025: $1,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,043 · Education: $23.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,042.70 |
| Education | $23.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $785.78 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $391.49 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $311.81 | 2022-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $309.87 | 2025 | Rezdiffra |
| Genzyme Corporation | $259.35 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $225.60 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $220.89 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Ardelyx, INC. | $204.93 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $196.78 | 2023-2025 | Wegovy, Saxenda |
| Regeneron Healthcare Solutions, INC. | $143.60 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $124.74 | 2023 | Epclusa |
| Celgene Corporation | $79.84 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $51.86 | 2025 | Vowst |
| Lilly USA, LLC | $41.03 | 2023-2025 | Omvoh |
| Organon LLC | $33.60 | 2025 | Hadlima, Renflexis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $31.08 | 2022 | |
| Celltrion USA INC. | $23.70 | 2024 | Zymfentra |
| Merck Sharp & Dohme LLC | $21.89 | 2023 | Dificid |
| Ipsen Biopharmaceuticals, INC | $14.86 | 2024 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.